Background-Pituitary apoplexy (PA) often presents with acute headache and neuro-ophthalmic manifestations, including ocular motility dysfunction (OMD) from cranial nerve palsies (CNPs). Our goal was to describe the epidemiology and outcomes of OMD in a large, single-center series of PA patients.
Introduction
Pituitary apoplexy (PA) is a potentially life-threatening clinical syndrome occurring after rapid expansion of the contents of the sella turcica, generally caused by hemorrhage within or infarction of a pre-existing pituitary adenoma. [1] [2] [3] Clinical presentations range from isolated headache to a conglomerate of additional symptoms including vomiting, altered consciousness, visual loss, and diplopia. 4, 5 In PA, diplopia arises from ocular motility dysfunction (OMD) from cranial nerve palsies (CNPs, which have been reported in 40-100% of patients with PA. 5 However, limited data regarding the neuro-ophthalmic presentation of OMDs in PA patients are available, especially when altered mental status is present or immediate surgery is performed. 5 In those cases, neuro-ophthalmic examination is often postponed and sometimes never performed. The aim of our study was to describe the characteristics of OMDs in PA patients, and to analyze the relationship between patient clinical outcomes and neuro-ophthalmologic, pathologic, endocrine, and radiologic findings.
Materials and Methods
The study was approved by our university's Institutional Review Board.
Inclusion criteria and patient characteristics
All consecutive charts of patients with PA seen at our institution's Pituitary Center between January 1995 and December 2012 were reviewed. PA was defined as a radiologically, surgically, or pathologically confirmed hemorrhagic or necrotic pituitary tumor in a patient with acute headache and/or visual changes. 6 The following data were collected for each patient: age, gender, date of presentation, clinical symptoms (headaches, visual loss, diplopia, and altered mental status), size of the tumor, endocrine status (secreting/nonsecreting, panhypopituitarism), surgical or medical management, date of surgery and, if any, dates of neuro-ophthalmic evaluations. PA patients (with or without OMD) seen at least once in our neuro-ophthalmology service were included in the subsequent analyses.
Neuro-ophthalmic evaluation
All patients seen in our neuro-ophthalmology service were evaluated in a standardized fashion. The following data were collected at presentation and at every follow-up visit: 1) best corrected Snellen visual acuity (VA) or VA with pinhole (converted into logMAR for statistical analysis); 2) formal visual fields (Humphrey visual field (HVF) and Goldmann visual field (GVF)) were obtained, and were graded according to their pattern (bitemporal hemianopia, homonymous hemianopia, or unilateral visual field defect) and size (small=less than a quadrant, partial=at least an entire quadrant, complete=involving the entire hemifield) and when HVF was performed, the mean deviation (MD) was recorded; 3) ocular motility; 4) pupil examination; and 5) fundus examination.
In patients with OMD, the time to recovery after surgery was assessed when follow-up examinations were available. When patients did not have a neuro-ophthalmic examination prior to surgery, the bedside history and physical examination performed by the neurosurgeon was obtained and included patient-reported symptoms of visual loss and diplopia, ocular motility examination, and confrontation visual field examination.
Statistical analysis
Descriptive statistics were calculated for all variables of interest, both overall and for patients seen in the neuro-ophthalmology unit. Data were collected and analyzed using Stata 1998 and R 3.2.2. A t-test was used to compare continuous variables. A χ 2 test with Yates' correction was used to compare qualitative variables. Fisher's exact test was employed when cell sizes were small (N≤5). To deal with inter-eye, intra-patient correlations, VA and MD for the right and left eyes were averaged for each patient. Logistic regression was used to assess whether OMD was in independent risk factor for visual loss, panhypopituitarism, and altered mental status controlling for tumor maximum diameter, age, and sex. A p-value <0.05 was considered as statistically significant.
Results
Of the 235 patients with PA, 147 had surgery (median time to surgery post-presentation: 21 days) and 88 were treated only medically. Fifty-nine (25%) had at least one documented OMD and only 3 of them did not undergo surgery (Table 1) . Patients with OMD were more likely to be men (59% vs. 36%, p=0.002). Altered mental status (14% vs. 5%, p=0.03) and visual loss (64% vs. 35%, p<0.001) were more frequently reported in patients with OMD than those without OMD. Of the 147 patients who had surgery, 57 were seen by neuroophthalmology and 27 of them had OMD.
Initial presentation
Twenty of these 27 PA patients with OMD were seen by neuro-ophthalmology prior to surgery. The 7 remaining patients were seen in neuro-ophthalmology after surgery (4 within one month and the other within 5 months of surgery), and data regarding their initial presentation were collected from the neurosurgeon's examination. Figure) -CNP VI was the most frequent (n=21 eyes), followed by CNP III (n=17) and CNP IV (n=7). CNP VI was bilateral in 3 patients. Two of these patients had a large sellar mass invading both cavernous sinuses, and they both had other CNPs (one had associated bilateral CNP III and CNP IV, and one had CNP III, CNP IV and CNP VI in only one eye); in the third patient, the suprasellar mass was abutting both cavernous sinuses. In the 17 eyes with CNP III, the pupil was involved in 6 eyes and ptosis was present in 11 eyes. CNP IV was always associated with another CNP in the same eye.
a. Cranial nerve palsies (Table 2;
b. Visual acuity-Median VA in OMD patients was worse, but not significantly different, than the median VA of patients without OMD (0.35 [IQR: 0.05-0.87] vs. 0.1 logMAR [IQR: 0.1-0.35]; p=0.17). Among the 27 patients seen in neuro-ophthalmology, 6 (22%) patients with OMD had at least one eye worse than 20/200 vs. 7 (23%) patients in the non-OMD group.
c. Visual field (Table 3 )-Forty-four eyes had a visual field examination, and 26 (59%) of these had a pituitary-tumor-related visual field defect. Twelve patients had a bitemporal hemianopia (including one junctional syndrome) and 2 patients had a unilateral optic neuropathy. Median MD in OMD patients was lower, but not significantly different, from median MD of patients without OMD (−6.58 [IQR: −2.25, −9.31] vs. −4.62 [IQR: −1.88, −11.54]; p=0.98).
Endocrine findings
Of the 235 overall patients with PA, secreting adenomas were less frequent in patients with OMD (22% vs. 33%, p=0.11), and instead patients with OMDs were significantly more likely to have panhypopituitarism (e.g., 31% vs. 14%, p=0.005). Only 14% of secreting pituitary adenomas with apoplexy exhibited OMD whereas 44% of PA patients with panhypopituitarism had OMD (p<0.001). There were no significant differences in the axis deficiencies (Table 1) , except for the gonadal axis deficiency, which was more common in patients with OMD (37% vs. 84%, p=0.04).
Radiologic findings
The tumor's radiological size was significantly larger in patients with OMD (mean maximum diameter: 2.6 vs. 2.0 cm; p<0.001) as were the measurements in every plane ( Table 1 ). All patients exhibited hemorrhage and/or signs of necrosis of the pituitary gland. Various mechanisms of nerve compression were observed including unilateral or bilateral cavernous sinus invasion (16 patients, including 7 with a single CNP VI, 1 with a single CNP III and the remaining had multiple CNPs), abutment without invasion of the cavernous sinuses (9 patients, including 8 with a single CNP III and 1 with a single CNP VI), and nerve compression outside of the cavernous sinus (2 patients with CNP VI). When compression of the nerves occurred outside of the cavernous sinus, there was invasion of the clivus along the route of CN VI.
Post-operative examination (Table 4)
Overall, patients with OMD were more likely to undergo surgery (95% vs. 52%, p<0.001; Table 1 ). Twenty-four patients had at least one neuro-ophthalmic evaluation after surgery. Surgery occurred ≤30 days post-presentation in 23 (96%; median 12 days). Median VA improved from 0.28 (IQR: 0.07-1.07) preoperatively to 0.1 (IQR: 0.0-0.2) postoperatively (p=0.001). Forty-eight eyes had a visual field examination and 16 of 48 (33%) had at least a small hemianopic defect. Seven patients had a bitemporal hemianopia and 2 patients had a unilateral optic neuropathy. All patients with secreting adenomas who did not undergo surgery had prolactinomas. OMD resolved in 3 of 24 (12%) patients within one month, in 13 of 21 (62%) patients within 6 months (3 lost to follow-up), and 17 of 19 (89%) within one year (2 additional lost to follow-up). No patient experienced aberrant regeneration of CN III after surgery. Surgery occurred ≤14 days post-presentation in 16/18 (89%) of resolved vs. 4/6 (67%) of cases who did not resolve or had incomplete follow-up at one year (p=0.25).
Pathology findings
In the overall series of PA patients, 110 underwent surgery of which 51 (46%) had only necrosis of the pituitary gland. In patients with OMD, necrosis of the gland was more frequently reported, with 58% of the patients having only necrosis of the pituitary gland, 9% both necrosis and hemorrhage, and 23% only hemorrhage. In the group without OMD, 37% of the patients had a necrotic only PA, 8% had both necrosis and hemorrhage, and 22% had hemorrhage only in the pituitary gland. There were significantly more patients with necrosis alone in the group with OMD vs. without OMD (p = 0.03).
Multivariable analysis
Multivariable logistic regression models controlling for maximum tumor diameter, age, and sex supported OMD as an independent risk factor for visual loss (odds ratio [OR] = 2.6; 95%CI: 1.2-5.3; p=0.007) and panhypopituitarism (OR = 2.9; 95%CI: 1.2-6.2; p=0.008), but not altered mental status (OR = 2.6; 95%CI: 0.83-8.5; p=0.10).
Discussion
Pituitary apoplexy commonly presents with neuro-ophthalmic symptoms and signs. In our large, single-center series of PA patients, 25% had uni-or bilateral OMDs at presentation. In the neurosurgical literature, several retrospective case series of PA patients report on OMD, but very few provide detailed neuro-ophthalmic data. In these series, OMD was reported to occur in 16-100% of PA patients. 2, 3, In our series, the most common OMD was CN VI followed by CN III, consistent with several previous reports, 7,10-12 although other series have reported more frequent CN III than CN VI involvement. 3, [13] [14] [15] [16] 9, [17] [18] [19] [20] 31 Our higher frequency of CN compression within the cavernous sinuses (14 patients) vs. abutment without invasion of the cavernous sinuses (10 patients) may partially explain the higher prevalence of CN VI vs. CN III in our series. This is because abutment without invasion most commonly results in CNP III since CN III is located in the same horizontal plane as the pituitary gland, 32 and this pattern was also seen in our series. However, direct CN III compression outside the cavernous sinus is also possible. For example, Kobayashi et al. reported 2 cases of isolated CNP III in PA without cavernous sinus invasion in which the tumor had some mass effect on CN III at the level of the oculomotor trigone after erosion of the posterior clinoid process. 33 CN VI may also be involved outside the cavernous sinus at the level of Dorello's canal. 34 In fact, 2 of our patients with isolated CNP VI had involvement of the clivus, neither with invasion of the cavernous sinus. One of these patients had a bilateral CNP VI that resolved after the clivus was opened during the procedure even though a coexisting abutment of the cavernous sinus persisted post-operatively, strongly suggesting that the bilateral CNP VI occurred at the level of the clivus rather than from the cavernous sinus abutment.
In our series, all CNP IV occurred in association with other CNPs, suggesting that an isolated CNP IV is very unlikely to be secondary to PA. To our knowledge, there is no such report in PA, and we are aware of only one published case of isolated CNP IV in the setting of pituitary macroadenoma. 21 While we found the VA of our patients with OMD to be worse at presentation compared to those without OMD, the difference was not significant. Very few studies provide specific data on the VA of PA patients, especially specific to those with OMD. However, two studies have suggested a possible association between OMD and very poor VA, 7, 8 and another reported normal visual acuity in only 2 out of 7 eyes with OMD. 9 Among our patients with PA and OMD, nearly two thirds overall reported vision loss.
Given the high co-occurrence of OMD and vision loss in our patients, and that there is essentially no disagreement about the need for early surgery when vision loss is present in PA, it is unsurprising that all but three of our patients with OMD had surgery. Our nearly universal use of early surgical management makes it difficult for us to comment on the benefit or harm of later surgery in PA despite considerable controversy about the management of PA patients with OMD and no vision loss. Indeed, several studies report improvement after delayed surgery and even with conservative management, 19, 25, 35, 36 and Rajasakeran et al.'s 2010 proposed guidelines suggest that immediate surgery is not indicated for OMD without visual field defects or reduced VA. 22 Based primarily on descriptive case series, they further conclude that conservative management alone leads to OMD resolution typically within days or weeks. On the other hand, Verrees et al. advocate for early surgery, 23 which they and others have found to be a successful treatment for PA patients with OMD 3, 15, 9, 17, 8, 23 . Jho et al. also advocated for early surgery in patients with OMD and no visual loss in 2014 when they proposed a grading of PA syndromes from 1 (asymptomatic) to 5 (all patients with vision loss) with higher grades indicating a need for more urgent/timely surgical management. 24 Grade 4 included all patients with OMD but no visual loss (n=26), and all but 2 underwent surgery. Randeva et al. demonstrated that complete resolution of OMD was more frequently seen in patients operated within 8 days (73%) vs. later (42%). 18 In our study, all but one patient with OMD had surgery within one month of presentation, and his OMD did not resolve.
In our study, pituitary necrosis was more frequent than isolated hemorrhage on pathologic examination of the PA patients with OMD who had surgery. A previous report has suggested a less severe presentation of patients from pituitary infarction compared to hemorrhage, although 'ophthalmoplegia' was more frequent in patients presenting with both hemorrhage and infarction of the pituitary gland. 37 Our PA patients with OMD were also more likely to develop panhypopituitarism and endocrine deficiencies than those without OMD, likely due to the higher frequency of necrosis in the OMD vs. non-OMD group since necrosis is a known risk factor for endocrine deficiencies. 38 Finally, we note that the detailed assessment of subjects by neuro-ophthalmology may have been limited to subjects who were generally less urgent although patients are frequently assessed at bedside in the hospital or emergency department by our unit. Our results should be cautiously interpreted considering this potential source of selection bias. 
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Conclusion
Pituitary apoplexy frequently causes OMD, and OMD appears to be more frequently associated with visual loss at presentation, a higher risk of panhypopituitarism, and with necrosis rather than hemorrhage of the pituitary. In our series, nearly all OMD either improved or resolved within one year after surgery, suggesting that these patients may need to be observed for at least one year before recommending strabismus surgery. While early pituitary surgery appears to result in good outcomes, our nearly universal application of early surgery makes it difficult for us to comment on the relative merits or risks of later surgery.
Highlights
• Ocular motility dysfunction is common in pituitary apoplexy, occurring in a quarter of patients • Nearly all palsies resolved within 1 year of surgery, but our nearly universal use of surgery in pituitary apoplexy does not allow us to comment on the relative merits or risks of later surgery
• Ocular motility dysfunction is more frequently associated with vision loss, panhypopituitarism, and necrosis in pituitary apoplexy
Figure.
Flow chart of patient characteristics. Table 4 Cranial nerve palsies and visual function outcomes in the 24 patients seen by neuro-ophthalmology before and after surgery. 
